Work

Abstract CT235: MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan versus trabectedin in patients with de-differentiated liposarcomas

Year: 2022

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2022-ct235

Authors: Mrinal M. Gounder, Gary K. Schwartz, Robin L. Jones, Sant P. Chawla, Victoria S. Chua-Alcala, Silvia Stacchiotti, Andrew J. Wagner, Gregory M. Cote, Robert G. Maki, Hanna Kosela-Paterczyk, Dale R. Shepard, Naisargee Shah, Richard Bryce, Robert C. Doebele, Shreyaskumar Patel

Institutions: Memorial Sloan Kettering Cancer Center, Columbia University, Institute of Cancer Research, Royal Marsden Hospital, Sarcoma Oncology Center, Fondazione IRCCS Istituto Nazionale dei Tumori, Dana-Farber Cancer Institute, Massachusetts General Hospital, Abramson Cancer Center, University of Pennsylvania, The Maria Sklodowska-Curie National Research Institute of Oncology, Cleveland Clinic, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Sarcoma Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4282963912

Cites:

Cited by:

Related to: 10